Skip to main content
$6.46 -$0.16 (-2.4%)

04:00 PM EDT on 03/17/23

Iovance Biotherapeutics Inc (NASDAQ:IOVA)

CAPS Rating: 2 out of 5

Current Price $6.46 Mkt Cap $1.4B
Open $6.60 P/E Ratio 0.00
Prev. Close $6.46 Div. (Yield) $0.00 (0.0%)
Daily Range $6.38 - $6.60 Volume 6,500
52-Wk Range $5.42 - $18.73 Avg. Daily Vol. 4,298,642


How do you think NASDAQ:IOVA will perform against the market?

Add Stock to CAPS Watchlist

All Players

32 Outperform
21 Underperform

All-Star Players

7 Outperform
12 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:IOVA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (99.75)
Submitted June 08, 2016

#zzporte has owned Lion since 2014 but I never could get excited enough about the position to enter a green thumb. The stock has gyrated quite a bit since we took our initial position but we never took advantage of the cycles and I recently… More


Fools bullish on NASDAQ:IOVA are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about IOVA.


Member Avatar LohShiSan (95.92) Submitted: 5/9/2020 3:03:38 AM : Outperform Start Price: $33.58 NASDAQ:IOVA Score: -119.73

With the goal of stomping out cancer, Iovance develops transformative immuno-oncology tumor-infiltrating lymphocytes (TIL) therapies that use the power of a patient’s own immune system.After its collaborator, Moffitt Cancer Center, provided an update on the Phase 1 testing of TILs plus nivolumab in CKI-naïve metastatic non-small-cell lung carcinoma (NSCLC) patients, the stock is on Wall Street’s radar. In order to be eligible, patients needed to be anti-PD-1 naïve and at least one safely accessible metastasis from where TILs were isolated had to be present.Looking at the data, the therapy was effective in 25% of patients, with two complete responses recorded. On top of this, the key analysis indicates that in order to spur a clinical response, TILs need to survive and circulate systematically.Further explaining this, H.C. Wainwright’s Joseph Pantginis noted, “Importantly, the authors also demonstrated that neoantigen positive T cells represented 21% of total TIL clonotypes. Although TIL clonotype persistence declines with time in the blood of these patients, persistent and stable levels of infused T cells associated with higher tumor killing and response. Thus, we believe that methods to enrich for these TIL populations, such as Iovance’s next generation TILs could be critical to drive better clinical responses.” As NSCLC is a notoriously difficult indication to address, Pantginis argues that the results should be interpreted as a major positive. With this in mind, he left a “buy” rating on IOVA. Along with his bullish call, the analyst lifted the price target from $36 to $48. This brings the upside potential to 50%. With 100% Street support, or nine “buy” ratings set in recent months, the consensus is unanimous: IOVA is a “strong buy.”


Member Avatar techjunkie89 (21.46) Submitted: 5/3/2020 11:27:15 PM : Outperform Start Price: $31.68 NASDAQ:IOVA Score: -118.52

Leading cell therapy player with efficacy shown in solid tumors, strong buyout potential


Member Avatar zzlangerhans (99.75) Submitted: 6/8/2016 9:27:33 AM : Underperform Start Price: $8.20 NASDAQ:IOVA Score: +105.69

#zzporte has owned Lion since 2014 but I never could get excited enough about the position to enter a green thumb. The stock has gyrated quite a bit since we took our initial position but we never took advantage of the cycles and I recently liquidated the last of our position. The impetus to get out of Lion was a very weird day of trading last Friday in which the stock jumped from 6 to the mid 8's after announcement of a large below market dilutive financing at 4.75. I've never seen a stock rise after a below market financing before, and I never would have imagined it could happen by 50%. Usually a below market financing results in the stock closing even lower than the financing price because the discount is perceived as a sign of weakness. In this case the effective market cap rose from 292M (6 x 49M shares) to 593M (8.6 x 69M shares) during the trading day. That's an additional 300M in cap for raising 100M in cash.

I didn't see much commentary pointing out this completely bizarre reaction in share price, athough there were a couple of articles pointing out the simultaneous announcement of a new CEO. I'm sure the new CEO is great, but she wasn't the CEO of anything a month ago and no one hired her to be their CEO then. Just saying. And no one executive is worth 200M of additional cap anyway. Meanwhile, Lion continues the excruciatingly slow progress of their TIL pipeline. I feel like I've been hearing about TILs since I was in high school, and if they were going to be anything they would have been something by now. Lion hasn't even completed enrollment in a midstage trial. Before long this stock is going to find its way back to the 4.75 level that the recent investors got to buy at.


Find the members with the highest scoring picks in IOVA.

Score Leader


SueInVirginia (83.08) Score: +465.74

The Score Leader is the player with the highest score across all their picks in IOVA.

Member Name Member
Call Time
Score Commentary
DorminABC 99.77 7/25/2011 Underperform NS $154.00 -95.81% +192.45% +288.26 0 Comment
Zencyclone 29.86 3/17/2015 Underperform 5Y $13.32 -51.61% +87.70% +139.31 0 Comment
monkeyjaws 42.81 3/12/2015 Underperform 5Y $12.39 -47.98% +88.31% +136.30 0 Comment
GreenAB 29.28 3/12/2015 Underperform NS $11.40 -43.46% +89.92% +133.39 0 Comment
Mangot1me 45.79 3/24/2015 Underperform 5Y $12.23 -47.30% +85.77% +133.07 0 Comment
roolbreakers 91.70 8/15/2016 Underperform 5Y $9.11 -29.25% +78.09% +107.35 0 Comment
zzlangerhans 99.75 6/6/2016 Underperform 1Y $8.20 -21.39% +84.30% +105.69 2 Comments
OttoLutz 84.08 7/19/2019 Underperform 5Y $26.12 -75.33% +30.29% +105.62 0 Comment
ClientNein 100.00 6/19/2019 Underperform 5Y $22.57 -71.44% +33.25% +104.70 0 Comment
jed71 98.38 7/7/2014 6/11/2019 Underperform 5Y $6.90 -6.59% +97.47% +104.07 4 Comments

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for IOVA.